Glutaurine is formed from the amino group of taurine with the gamma-carboxy group of L-glutamic acid. It was originally discovered in the parathyroid. Evidence has been found suggesting that glutaurine plays a role in peripheral thyroid hormonal regulation. Glutaurine increases triiodothyronine (T3) levels, but does not alter thyroxine (T4) levels. Glutaurine was also shown to prevent electroconvulsive shock-induced amnesia by counteracting the shock effect on the memory consolidation phase. Other roles that have been suggested for glutaurine include roles as a mouse metabolite, a mammalian metabolite, a human metabolite, an anticonvulsant, an anxiolytic drug and a hormone.

Mefenidil has been reported to be a selective cerebral vasodilator. It significantly increased cerebral blood flow (without stimulation of O2 uptake) and lowered cerebral vascular resistance without having significant effects in other circulatory regions. Increase in cerebral blood flow is not mediated via the beta-adrenergic receptor as the effect was not blocked by propranolol. However, the clinical usefulness of mefenidil as a cerebral vasodilator may be limited by the accompanying arterial hypotension due to systemic vasodilation, which was most prominent in heart and gut.

Fuprazole was developed as a bronchodilator that has never been marketed. Information about the current use of this compound is not available.

Pirazmonam is a potent anti-gram-negative monobactam that is differentiated from aztreonam by its high intrinsic activity against Ps. aeruginosa and good activity against Pseudomonas species. Pirazmonam has generally poor activity against gram-positive aerobic bacteria and anaerobic bacteria. Pirazmonam is a Trojan Horse molecule containing a b-lactam antibiotic that has been developed based on bacterial iron uptake systems. It features high structural similarity to aztreonam attached to a 3-hydroxy-4-pyridinone iron chelating group. Pirazmonam exhibited strong affinity to penicillin-binding protein 3 (PBP3) of Escherichia coli and moderate to negligible affinity to the other E. coli PBPs.

Persilic acid is a virucide, hemostatic, capillary protective agent. 0.1% aqueous solution of K salt is used as a fluorescent acid-base indicator.

Etaqualone (Aolan, Athinazone) is an analog of the hypnotic methaqualone, a non-barbiturate sedative it was developed and marked in France. Etaqualone possesses sedative and hypnotic properties and was used to treat insomnia resulting from its agonist activity at the β subtype of the GABAa receptor.

Carbon Monoxide C-11 is a colorless, odorless, and tasteless flammable radiolabeled gas patented by Glaxo Group Limited as imaging agent

Dichloroxylenol is a bactericide, preservative and deodorant. It is often used in the preparation of antiseptic and deodorant lotions and bath preparations. Dichloroxylenol also showed slightly greater activity against S. aureus Oxoid 701/1 Lot 610254 than against Escherichia coli and Salmonella typhi, indicating a probable role for cell wall in the susceptibility of bacteria to dichloroxylenol. The efficacy of either povidone-iodine (Betadine) or dichloroxylenol (Septocid) intrauterine infusions on the treatment of endometritis and/or cervicitis in cows was examined. The recovery and conception rates obtained after Betadine treatment were better than those obtained after Septocid. Moreover, healthy cows and those inseminated before post-partum day 180, having no more than 4-7 previous services, responded well to either Betadine or Septocid treatment.

Climiqualine is a compound developed by Hoersht AG and claimed to possess hypolipemic and hypoglycemic activities in rats and rabbits.

Difebarbamate is a barbituric acid derivative. It is a hypnotic drug. Difebarbamate is a component of Tetrabamate complex, which was introduced for clinical use in the treatment of alcoholism and various types of drug dependence. After oral administration of difebarbamate, the compound was completely metabolized and three metabolic pathways were observed: oxidation of Cl of the n-butyl chain which leads to the oxygen dealkylation; hydrolysis of the carbamoyloxy group; oxidation of the benzene ring in position 4. Tetrabamate can induce hepatotoxicity, probably due to an idiosyncratic metabolic mechanism. Despite restrictions on its indications and treatment duration introduced in 1997, cases of severe liver damage have continued to be notified in France.